As far as I understand, it’s probably a bit further out for psilocybin. Compass Pathways are the furthest along I believe, with Phase 3 reads-outs expected next year for treatment resistant depression. Unless it’s fast-tracked, 2025 seems more likely.
2024 can happen for MDMA, though. MAPS has completed (I believe) Phase 3B for comparing PTSD.
It’s happening, but slowly. I fully expect these wonderful molecules to be widely available in clinical settings within 5 years, including LSD and ibogaine (which seems particularly promising for addiction treatment)